Indaptus Therapeutics (INDP) Stock: Buy, Sell, or Hold?
INDP - Indaptus Therapeutics, Inc. Common Stock
$2.38
0.26 (12.26%)
▲
5d:
-38.18%
30d:
+103.42%
90d:
-16.49%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 11, 2026
Get Alerted When INDP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: INDP is down 38.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: INDP is down 38.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: INDP is currently trading at $2.38, which is considered fair relative to its 30-day fair value range of $1.32 to $3.53.
Technical Outlook: Technically, INDP is showing sideways momentum. Immediate support is located at $1.94, while resistance sits at $4.22. The stock is showing strong short-term momentum, up 12.3% recently.
Market Sentiment: INDP scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.00 (+320.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, INDP is showing sideways momentum. Immediate support is located at $1.94, while resistance sits at $4.22. The stock is showing strong short-term momentum, up 12.3% recently.
Market Sentiment: INDP scores 15/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $10.00 (+320.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$1.32 -
$3.53
Company Quality Score
38/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
55.3%
All Signals
- NEUTRAL: Price in fair range
- BEARISH: Weak technical setup (15/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+12.3%)
- BULLISH: Trading 320.2% below Wall St target ($10.00)
- WARNING: Composite score 38/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.32 -
$3.53
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$1.94
Resistance Level
$4.22
Current Trend
Sideways
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.53
Wall Street Target
$10.00
(+320.2%)
Share & Embed Analysis
Last updated: October 03, 2026 10:21 AM ET
Data refreshes hourly during market hours. Next update: 11:21 AM
Data refreshes hourly during market hours. Next update: 11:21 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INDP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$92 | 46 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 76 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 65 BUY |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 42 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$128 | 56 HOLD |
